IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

DERENZINI, ENRICO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.466
NA - Nord America 2.293
AS - Asia 1.897
SA - Sud America 152
OC - Oceania 53
AF - Africa 23
Continente sconosciuto - Info sul continente non disponibili 2
Totale 7.886
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.227
DE - Germania 804
CN - Cina 799
IT - Italia 577
GB - Regno Unito 502
SG - Singapore 477
SE - Svezia 331
FR - Francia 253
RU - Federazione Russa 230
IE - Irlanda 192
IN - India 150
ES - Italia 149
BR - Brasile 125
ID - Indonesia 107
HK - Hong Kong 94
JP - Giappone 92
NL - Olanda 90
CH - Svizzera 75
AU - Australia 49
FI - Finlandia 49
TR - Turchia 38
CA - Canada 37
GR - Grecia 33
BE - Belgio 26
MX - Messico 26
PL - Polonia 26
AT - Austria 24
KR - Corea 21
IR - Iran 18
TW - Taiwan 18
VN - Vietnam 18
DK - Danimarca 17
NO - Norvegia 16
PT - Portogallo 14
CZ - Repubblica Ceca 11
HU - Ungheria 11
UA - Ucraina 9
AM - Armenia 8
JO - Giordania 8
AR - Argentina 7
IL - Israele 7
PK - Pakistan 7
TH - Thailandia 7
PH - Filippine 6
BG - Bulgaria 5
CL - Cile 5
MA - Marocco 5
PE - Perù 5
EE - Estonia 4
IQ - Iraq 4
NZ - Nuova Zelanda 4
TN - Tunisia 4
ZA - Sudafrica 4
CI - Costa d'Avorio 3
CO - Colombia 3
EC - Ecuador 3
EG - Egitto 3
KZ - Kazakistan 3
RO - Romania 3
SI - Slovenia 3
UY - Uruguay 3
AE - Emirati Arabi Uniti 2
BA - Bosnia-Erzegovina 2
LA - Repubblica Popolare Democratica del Laos 2
LT - Lituania 2
MK - Macedonia 2
MY - Malesia 2
PS - Palestinian Territory 2
UZ - Uzbekistan 2
AL - Albania 1
AP - ???statistics.table.value.countryCode.AP??? 1
AZ - Azerbaigian 1
BD - Bangladesh 1
BO - Bolivia 1
BY - Bielorussia 1
CU - Cuba 1
DO - Repubblica Dominicana 1
EU - Europa 1
GH - Ghana 1
GT - Guatemala 1
HR - Croazia 1
IS - Islanda 1
KW - Kuwait 1
LU - Lussemburgo 1
LV - Lettonia 1
MO - Macao, regione amministrativa speciale della Cina 1
MU - Mauritius 1
NG - Nigeria 1
NP - Nepal 1
SC - Seychelles 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 7.887
Salva come PNG Salva come JPEG
Città #
Frankfurt am Main 547
Southend 404
Singapore 317
Chandler 222
Fairfield 218
Milan 193
Dublin 192
Princeton 158
Ashburn 131
Beijing 108
Council Bluffs 106
Jakarta 95
Wilmington 92
Seattle 87
Woodbridge 86
Houston 85
Cambridge 79
Des Moines 68
Shanghai 67
Ann Arbor 60
Bengaluru 53
Barcelona 45
Santa Clara 45
New York 43
Eitensheim 39
Hong Kong 38
Helsinki 36
Guangzhou 30
Nanjing 30
Central District 29
Tokyo 29
Hangzhou 28
Berlin 27
Moscow 27
Tianjin 26
Nuremberg 25
Paris 24
Lugano 23
Redwood City 23
Rome 23
San Diego 22
Los Angeles 20
Vienna 19
London 18
Wuhan 17
Istanbul 16
Madrid 16
Rochester 16
Sydney 16
Athens 15
Brussels 14
Norwalk 14
Chicago 13
Mumbai 13
Silver Spring 13
Southampton 13
Trieste 13
Bologna 12
Hanover 12
Yubileyny 12
Boston 11
Brisbane 11
Dearborn 11
Phoenix 11
Salamanca 11
São Paulo 11
Zurich 11
Cangzhou 10
Rockville 10
Toronto 10
Bühl 9
Genoa 9
Melbourne 9
Pune 9
Thessaloniki 9
Upper Marlboro 9
Xian 9
Amman 8
Amsterdam 8
Belo Horizonte 8
Bern 8
Central 8
Düsseldorf 8
Munich 8
Murcia 8
Nanchang 8
Nanning 8
Naples 8
Redmond 8
Seoul 8
Shenyang 8
Sunnyvale 8
Turin 8
Warsaw 8
Yerevan 8
Angers 7
Bari 7
Catania 7
Chengdu 7
Florence 7
Totale 4.611
Salva come PNG Salva come JPEG
Nome #
Genetic and Phenotypic Attributes of Splenic Marginal Zone Lymphoma 1.683
A 3-gene signature based on MYC, BCL-2 and NFKBIA improves risk stratification in diffuse large B-cell lymphoma 241
[¹⁸ F]-FDG PET radiomic model as prognostic biomarker in diffuse large B-cell lymphoma [$\less$sup$\greater$18$\less$/sup$\greater$F]-{FDG} {PET} radiomic model as prognostic biomarker in diffuse large B-cell lymphoma] 240
Dissection of DLBCL Microenvironment Provides a Gene Expression-Based Predictor of Survival Applicable to Formalin-Fixed Paraffin-Embedded Tissue 235
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study 204
Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphoma 183
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 175
Genomic alterations of ribosomal protein genes in diffuse large B cell lymphoma 170
BET Inhibition-Induced GSK3β Feedback Enhances Lymphoma Vulnerability to PI3K Inhibitors 163
Bronchus-associated lymphoid tissue lymphomas : an update of a rare extranodal maltoma 119
Gene expression profiling and FDG-PET radiomics uncover radiometabolic signatures associated with outcome in DLBCL 118
Influence of Donor and Recipient Gender on Telomere Maintenanceafter Umbilical Cord Blood Cell Transplantation: A Study by the GruppoItaliano Trapianto Di Midollo Osseo 118
Gemcitabine as single agent in pretreated T-cell lymphoma patients: Evaluation of the long-term outcome 109
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies 108
BIA-ALCL in patients with genetic predisposition for breast cancer: our experience and a review of the literature 107
Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma 106
Blastic plasmacytoid dendritic cell neoplasm : State of the art and prospects 105
Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma : the Italian experience and results of its use in daily clinical practice outside clinical trials 101
SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort 97
Phase II trial of short-course R-Chop followed by 90Y- ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients 97
Y-90-Ibritumomab Tiuxetan Consolidation After Autologous Stem Cell Transplantation Improves Survival of Patients with Intermediate-/High-risk Diffuse Large B-cell Lymphoma Not Responding Adequately to First-line Treatment 95
FDG-PET in the assessment of patients with follicular lymphoma treated by ibritumomab tiuxetan Y 90: Multicentric study 94
Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma 93
Peripheral t‐cell lymphoma, not otherwise specified : Clinical manifestations, diagnosis, and future treatment 93
Characterization of a c-Rel inhibitor that mediates anticancer properties in hematologic malignancies by blocking NF-κB-controlled oxidative stress responses 92
A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients 84
The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma 83
Pre-existing immune checkpoints activation predicts relapse after allogeneic stem cell transplantation in lymphoma 83
Plasmablastic lymphoma : One or more tumors? 79
Corrigendum: Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue (Annals of Oncology (2018) 29 (2363-2370) DOI: 10.1093/annonc/mdy450) 78
Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma 77
Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report 77
Collection of Hematopoietic Stem Cells after Previous Radioimmunotherapy is Feasible and Does Not Impair Engraftment after Autologous Stem Cell Transplantation inFollicular Lymphoma 76
The histone deacetylase inhibitor entinostat (sndx-275) induces apoptosis in hodgkin lymphoma cells and synergizes with bcl-2 family inhibitors 74
The identification of TCF1+ progenitor exhausted T cells in THRLBCL may predict a better response to PD-1/PD-L1 blockade 72
Predictive and prognostic molecular factors in diffuse large b-cell lymphomas 72
Predicting treatment outcome in classical Hodgkin lymphoma: Genomic advances 71
High efficacy of the MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis, a 20 year experience 71
Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia 71
MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis: Experience on seven patients 68
Treatment of colorectal cancer liver metastases 67
Prognostic value of interim positron emission tomography in patients with peripheral T-cell lymphoma 66
Allotransplant in relapsed or refractory aggressive T-cell lymphomas: Retrospective monocentric analysis of 14 patients 64
Treating hematological malignancies with drugs inhibiting ribosome biogenesis : When and why 63
Chemotherapy after PD-1 inhibitors in relapsed/refractory Hodgkin lymphoma: Outcomes and clonal evolution dynamics 63
Editorial: Novel treatments for diffuse large B-cell lymphoma: The post-CART era 61
Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in untreated follicular lymphoma) 59
An isolated penile mass in a young adult turned out to be a primary marginal zone lymphoma of the penis : a case report and a review of literature 59
Long telomeres at baseline and male sex are main determinants of telomere loss following chemotherapy exposure in lymphoma patients 58
Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: A new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients 58
Association of essential thrombocythemia and non-Hodgkin lymphoma: A single-centre experience 55
Therapeutic implications of intratumor heterogeneity for TP53 mutational status in Burkitt lymphoma 54
Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 trial 52
Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: A multicenter retrospective study 51
Bendamustine: Role and evidence in lymphoma therapy, an overview 51
Dissecting diffuse large b-cell lymphomas of the “not otherwise specified” type: The impact of molecular techniques [version 1; referees: 2 approved] 49
A phase I study of continuous hepatic arterial infusion of Irinotecan in patients with locally advanced hepatocellular carcinoma 49
CNS recurrence of primary mediastinal large b-cell lymphoma after complete remission 49
Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified 48
Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin 47
Adjuvant systemic chemotherapy after putative curative resection of colorectal liver and lung metastases 46
Complete response of relapsed systemic and cutaneous anaplastic large cell lymphoma using brentuximab vedotin: 2 Case reports 44
A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma 42
A phase ii trial of short course fludarabine, mitoxantrone, rituximab followed by 90y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma 41
VNCOP-B plus rituximab in the treatment of diffuse large B-cell lymphoma in the elderly 39
Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: Evaluation of the long-term outcome 38
Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma 38
An integrated prognostic model for diffuse large B-cell lymphoma treated with immunochemotherapy 37
Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma 37
Slow evolution of liver metastasis from colon cancer 37
Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma 37
NR1H3 (LXRα) is associated with pro-inflammatory macrophages, predicts survival and suggests potential therapeutic rationales in diffuse large b-cell lymphoma 36
Successful combination treatment of clofarabine, cytarabine, and gemtuzumab-ozogamicin in adult refractory B-acute lymphoblastic leukemia 36
Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma 35
Treatment of hepatic metastases from colorectal cancer: Many doubts, some certainties 35
Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ) 33
Anti-PD1 Consolidation in Patients with Hodgkin Lymphoma at High Risk of Relapse after Autologous Stem Cell Transplantation: A Multicenter Real-Life Study 32
Targeting the JAK-STAT pathway in lymphoma: A focus on pacritinib 32
Long-term efficacy of the combination of lenalidomide and rituximab in elderly relapsed/refractory diffuse large B-cell lymphoma patients 32
Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13) 30
Gemcitabine 30
Severe peripheral motor neuropathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin 29
Hairy cell leukemia: Evaluation of the long-term outcome in 121 patients 29
Sequential therapy with alternating short courses of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) and R-FM (rituximab, fludarabine, mitoxantrone) followed by autologous stem cell transplantation results in long term remission in advanced follicular lymphoma 28
Extranodal marginal zone B-cell lymphoma of the lung: Experience with fludarabine and mitoxantrone-containing regimens 27
Extramedullary myeloid tumour of the stomach and duodenum presenting without acute myeloblastic leukemia: A diagnostic and therapeutic challenge 27
Primary bone lymphoma: Evaluation of chemoimmunotherapy as front-line treatment in 21 patients 26
Postchemotherapy PET evaluation correlates with patient outcome in paediatric Hodgkin's disease 25
The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines 23
Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma 23
Non-hodgkin lymphomas presenting as soft tissue masses: A single center experience and meta-analysis of the published series 22
Continuous venetoclax in treatment-naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study 18
Germline BRCA pathogenic variants in patients with ovarian cancer and post-poly (ADP-ribose) polymerase inhibitor myeloid neoplasms 17
Venetoclax Plus Intensified Chemoimmunotherapy as a Bridge to Allogeneic Stem Cell Transplantation in Richter Syndrome: Report of Two Cases 11
Immune Signatures Identify Patient Subsets Deriving Long-Term Benefit From First-Line Rituximab in Follicular Lymphoma 11
Germline BRCA pathogenic variants and hematologic adverse events in patients with ovarian carcinoma receiving PARP inhibitors: a retrospective cohort study 9
High-dose chemotherapy and autologous stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin Lymphoma in the era of PET-adapted strategies 8
Hairy cell leukemia with an atypical extranodal presentation: A clinicopathological analysis of four cases 7
Identification of Novel Potential Predisposing Variants in Familial Acute Myeloid Leukemia 6
null 3
Totale 8.321
Salva come PNG Salva come JPEG
Categoria #
all - tutte 30.430
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.430
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020321 0 0 0 0 0 0 0 0 0 123 152 46
2020/2021889 53 74 98 62 125 118 28 93 38 71 48 81
2021/20221.333 57 30 59 131 74 77 70 166 170 159 81 259
2022/20231.557 200 122 177 105 104 262 74 104 126 78 120 85
2023/20241.768 89 129 145 99 249 126 154 149 75 149 180 224
2024/20251.970 165 377 145 216 144 143 145 277 132 226 0 0
Totale 8.325